Title	New assessment
Title	RECIST response
Number of Patients Enrolled	11
Number of Patients Evaluable for Toxicity	11
Number of patients Evaluated for Efficacy	11
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0
Response Assessment PR	n = 1
Response Assessment SD	n = 7
Response Assessment PD	n = 3
(Median) Duration Assessments PFS	2.97 months, CI: 2.02–3.92
Outcome Notes
In patients without evaluation of efficacy, three patients were treated for less than one cycle because of adverse reactions, and one patient had not undergone imaging examination. In the apatinib plus standard chemotherapy group, two patients continued to receive the treatment, and seven patients had undergone apatinib therapy for more than 6 months. PFS was significantly longer in the experimental group than in the control group (median PFS 5.47 months [95% confidence interval (CI): 3.21–7.73] vs. 2.97 months [95% CI: 2.02–3.92], hazard ratio [HR]: 0.3347, p = .0068; Fig. 2). ORR and DCR were 27% and 95% for the experimental group compared with 9% and 73% for the control group (Fig. 1; Table 2), respectively. Because the number of patients is too small, therapeutic effect evaluation and statistical analysis of subgroup are not performed temporarily.